This panel will address the challenges encountered in encouraging and doing licensing and collaboration deals in fields where traditional market incentives, such as ROI, work poorly if at all. There are multiple examples of such fields in the life sciences: emerging infectious diseases, neglected tropical diseases, antibiotic resistance, and ultra-orphan genetic diseases and cancers. Public discourse has become stridently anti-patent in some of these fields, driven by the simplistic appeal of "access to medicines" and "drug pricing." We will address solutions ranging from alternatives to traditional milestones/royalties, liability and indemnity protections, and public funding.

Session Pricing:

$49